SCHEMBL1667911

SCHEMBL1667911

CCCCCCCCC=CCCCCCCCC(=O)N1CCOCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ KMT2A Q03164 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ CNR1 P21554 3/20 0.54
▸ CNR2 P34972 1/20 0.53
▸ GNAI3 P08754 1/20 0.53
▸ GNAI1 P63096 1/20 0.53
▸ TERT O14746 3/20 0.51
▸ PTPN1 P18031 3/20 0.51
▸ PPARG P37231 3/20 0.51
▸ PPARD Q03181 3/20 0.51
▸ PPARA Q07869 3/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ BLM P54132 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ FABP4 P15090 2/20 0.51
▸ FAAH O00519 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1667902 1.00 L3MBTL1 (0.56) L3MBTL1KMT2AMEN1TDP1CNR1
SCHEMBL11543721 0.96 CNR1 (0.59) L3MBTL1TDP1CNR1CNR2PPARG
SCHEMBL9806573 0.91 CNR1 (0.49) L3MBTL1KMT2AMEN1TDP1CNR1
SCHEMBL31429810 0.91 CNR1 (0.64) L3MBTL1KMT2AMEN1TDP1CNR1
SCHEMBL8971856 0.91 L3MBTL1 (0.67) L3MBTL1KMT2AMEN1TDP1GNAI3
SCHEMBL2982115 0.91 L3MBTL1 (0.67) L3MBTL1KMT2AMEN1TDP1GNAI3
SCHEMBL8972353 0.91 L3MBTL1 (0.67) L3MBTL1KMT2AMEN1TDP1GNAI3
SCHEMBL8971899 0.91 L3MBTL1 (0.67) L3MBTL1KMT2AMEN1TDP1GNAI3
SCHEMBL8973343 0.91 L3MBTL1 (0.67) L3MBTL1KMT2AMEN1TDP1GNAI3
SCHEMBL8972793 0.91 L3MBTL1 (0.67) L3MBTL1KMT2AMEN1TDP1GNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10370344-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders AVEXXIN AS (NO) 2019-08-06 — — US disclosed
EP-3431084-A1 ANTIINFLAMMATORY 2-OXOTHIAZOLES Avexxin AS (NO) 2019-01-23 — — EP disclosed
US-20170166539-A1 COMPOUND AVEXXIN AS (NO) 2017-06-15 — — US disclosed
US-9597318-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders AVEXXIN AS (NO) 2017-03-21 — — US disclosed
EP-2482815-A1 ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES Avexxin AS (NO) 2012-08-08 — — EP disclosed
US-20110136879-A1 COMPOUND AVEXXIN AS (NO) 2011-06-09 — — US disclosed
WO-2011039365-A1 ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES AVEXXIN AS (NO) 2011-04-07 — — WO disclosed
US-4144256-A FATTY AMIDE SUBSTITUTED WITH ACETYLTHIO GROUP OR GROUPS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1979-03-13 — — US disclosed
US-4092319-A CARBOALKOXY-METHYLTHIO-FATTY AMIDE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1978-05-30 — — US disclosed
US-4062841-A MICROBIOCIDE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1977-12-13 — — US disclosed
US-4061634-A Sulfur-containing antimicrobial ester-amides THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1977-12-06 — — US disclosed
US-4008137-A FROM 10-UNDECENOYLMORPHOLINE AND A DIALKYL PHOSPHITE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1977-02-15 — — US disclosed
US-3996353-A Phosphonated N,N-disubstituted fatty morpholines as bacterial and fungicidal agents THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1976-12-07 — — US disclosed
US-3988226-A BY FREE RADICAL ADDITION OF DIALKYL PHOSPHITES TO THE N,N-DISUBSTITUTED AMIDES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1976-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136879-A1 COMPOUND CBR1, CBR3, CCR1 L3MBTL1 757/4885KMT2A 4796/4885MEN1 2321/4885
US-20170166539-A1 COMPOUND CBR1, CBR3, CCR1 L3MBTL1 753/4885KMT2A 4797/4885MEN1 2314/4885
US-10370344-B2 2-oxothiazole compounds and method of using same for chronic inflammatory disorders CX3CR1, LTC4S, CBR1 L3MBTL1 351/4885KMT2A 4706/4885MEN1 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback